BARCELONA, Spain, March 4, 2026 /PRNewswire/ -- At the Mobile World Congress (MWC), vivo and the UNESCO Man and the Biosphere (MAB) Programme officially announced the launch of "Capture the Future: Global Youth Storytelling Initiative for People and Nature". This partnership empowers youth worldwide to utilize mobile imaging to document the intricate and harmonious relationship between humanity and nature, fostering a shared commitment to a sustainable global future.

Youth Leading the Story: Building a Shared Global Commitment
As mobile imaging technology matures, it has evolved into a vital medium for public observation and social engagement. Today's young creators are increasingly directing their lenses toward the intersection of social and environmental dynamics. As a pioneer in mobile imaging innovation, vivo has long been committed to supporting creators in using visual storytelling to reflect on real-world challenges and bridge the gap between individual perspectives and community action.
UNESCO Biosphere Reserves serve as "demonstration sites" that integrate ecological conservation with sustainable community development. These sites require the fresh, innovative expressions of the young generation to highlight successful models of sustainable living. Through this initiative, vivo and UNESCO MAB are systematically empowering youth to become core advocates for ecological documentation and the advancement of the United Nations Sustainable Development Goals (SDGs).
Yu Meng, Vice President of Imaging at vivo emphasized: "Meaningful technology starts with people and ends with a better society. Through this collaboration, we aim to translate our professional expertise in mobile imaging into tangible support for young creators worldwide as they document ecological biodiversity and community resilience. We aspire for vivo to be a trusted companion for youth exploring the world and shaping the future.
Prof. Antonio De Sousa Abreu, Director of the Division of Ecological and Earth Sciences at UNESCO added: "Young people are essential drivers of sustainable development. Their unique outlook and creative energy are invaluable. Through this partnership with vivo, we are providing a global platform for them to use the universal language of imagery to transform stories from Biosphere Reserves into real-world impact, driving progress in areas such as human-nature relationship, education and public science, as well as indigenous and local knowledge."
A Collaborative Journey: From Observation to Impact
The initiative launches with a global open call for visual storytelling submissions via UNESCO MAB youth networks, running from March to May. Centered on the synergy between biodiversity, climate resilience, cultural heritage, and sustainable innovation, the program aims to spotlight forward-thinking solutions through a youthful lens. Winners will travel to European biosphere reserves for the Global Youth Visual Storytelling Co-Creation Camp, where their narratives will help bridge the gap between humanity and the natural world, inspiring global action for a sustainable future.
To ensure these narratives achieve both technical excellence and environmental depth, participants will be guided by a "dual-mentor" team consisting of vivo imaging specialists and UNESCO sustainability experts. These immersive experiences, bolstered by regional capacity-building workshops, are designed to empower young participants to evolve from observers into influential storytellers. The journey will culminate in a global showcase, bringing these amplified youth perspectives to the world stage to drive meaningful impact.
Vision for a Resilient Future
Looking ahead, vivo and UNESCO MAB remain dedicated to mobilizing youth creativity to translate the complex actions of biosphere reserves into visually compelling narratives. By blending cutting-edge imaging technology with human-centric actions, this partnership seeks to transcend regional and cultural boundaries. Together, these visual stories will converge into a global movement for sustainable development, helping to build a more resilient, harmonious, and promising future for all.
About vivo
vivo is a technology company that creates great products based on a user-oriented value, with smart devices and intelligent services as its core. The company aims to build a bridge between humans and the digital world. Through unique creativity, vivo provides users with an increasingly convenient mobile and digital life. Following the company's core values, which include Benfen*, user-orientation, design-driven value, continuous learning and team spirit, vivo has implemented a sustainable development strategy with the vision of developing into a healthier, more sustainable world-class corporation.
While bringing together and developing the best local talents to deliver excellence, vivo is supported by a network of R&D centers in Shenzhen, Dongguan, Nanjing, Beijing, Hangzhou, Shanghai, Xi'an and more cities, focusing on the development of state-of-the-art consumer technologies, including 5G, artificial intelligence, industrial design, imaging system and other up-and-coming technologies. vivo has also set up an intelligent manufacturing network (including those authorized by vivo), with an annual production capacity of nearly 200 million smartphones. As of now, vivo has branched out its sales network across more than 60 countries and regions, and is loved by more than 500 million users worldwide.
*"Benfen" is a term describing the attitude on doing the right things and doing things right – which is the ideal description of vivo's mission to create value for society.
Stay informed of latest vivo news at https://www.vivo.com/en/about-vivo/news
Photo - https://mma.prnewswire.com/media/2926237/Unesco_Image.jpg

Bachem hat für das Geschäftsjahr 2025 robuste Zahlen vorgelegt und die durchschnittlichen Analystenschätzungen beim Umsatz wie beim Ergebnis übertroffen. Der Pharmazulieferer setzte 695,1 Millionen Franken um, ein Plus von 14,8 Prozent gegenüber dem Vorjahr; in Lokalwährungen lag das Wachstum sogar bei 19,2 Prozent. Im ersten Halbjahr war das Unternehmen in Lokalwährungen noch um 34 Prozent gewachsen. Unter dem Strich erzielte Bachem einen Reingewinn von 148,8 Millionen Franken und damit knapp 24 Prozent mehr als 2024. Damit lag das Unternehmen rund 30 Millionen Franken über der Konsensschätzung.
Auch auf operativer Ebene legte Bachem zu. Der EBITDA stieg um 21,8 Prozent auf 214,7 Millionen Franken, die Marge verbesserte sich um 1,8 Prozentpunkte auf 30,9 Prozent. Darin enthalten ist allerdings ein positiver Sondereffekt von 16,1 Millionen Franken aus der Standortentwicklung im Sisslerfeld sowie dem Verkauf eines Gebäudes in den USA. Bereinigt lag die EBITDA-Marge bei 28,6 Prozent und damit ungefähr auf Höhe der Markterwartungen. Aktionäre sollen an der Entwicklung teilhaben: Die Divende soll von 0,85 auf 0,90 Franken je Aktie erhöht werden.
Für Gesprächsstoff sorgt der Ausblick. Unter der neuen CEO Anne-Kathrin Stoller rückt Bachem von der bisher kommunizierten Marke eines Umsatzes von mindestens 1 Milliarde Franken ab, die 2026 erreicht werden sollte. Im aktuellen Communiqué wird dieses Mittelfristziel nicht mehr explizit erwähnt. Stattdessen stellt das Unternehmen für das laufende Jahr ein Umsatzwachstum von 35 bis 45 Prozent in Aussicht, was einer Spanne von 938 Millionen bis 1,008 Milliarden Franken entspricht. Schafft Bachem den oberen Rand, wäre die bisherige Zielmarke zwar erreicht – die weniger pointierte Formulierung dürfte aber einige Investoren veranlassen, ihre Erwartungen zu justieren.
Operativ richtet Bachem die Organisation auf weiteres Wachstum aus. 2025 investierte der Konzern 332,6 Millionen Franken über alle Standorte hinweg; im laufenden Jahr sollen die Investitionen auf über 400 Millionen Franken steigen. Hintergrund sind unter anderem mehrere Grossaufträge von Herstellern der stark nachgefragten Medikamenten zur Gewichtsreduktion. Gleichzeitig treibt Bachem den Ausbau neuer Kapazitäten voran: Die erste Bauetappe des Gebäudes K wurde Ende 2025 von der Aufsichtsbehörde Swissmedic inspiziert und freigegeben. Das Unternehmen, das Peptid-basierte Wirkstoffe für Indikationen wie Krebs, Diabetes und Fettleibigkeit liefert und parallel ein Standbein im Bereich Oligonukleotide aufbaut, setzt damit klar auf steigende Nachfrage – auch wenn es bei der kommunikativen Zuspitzung seiner Umsatzziele zurückhaltender geworden ist.